Replimune Group Inc —— 季度现金流量表 (NASDAQ:REPL) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 551.33 M469.51 M389.45 M333.59 M 负债总额 135.49 M132.79 M126.11 M123.05 M 权益总额 415.84 M336.71 M263.34 M210.54 M 负债及股东权益总额 551.33 M469.51 M389.45 M333.59 M 总债务 49.18 M49.61 M50.05 M50.49 M 净债务 -434.63 M-353.73 M-273.6 M-218.65 M

新闻

Replimune stock collapses 64% following FDA rejection

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

美国股市上涨；截至收盘道琼斯工业平均指数上涨0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study